Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference

Axsome Therapeutics highlighted growth across its commercial portfolio, an expanded sales force and several late-stage clinical programs at the H.C. Wainwright Global Investment Conference. The update signals continued commercialization investment and pipeline progress, but disclosed no financial results, clinical data, or specific guidance changes.